Posted by Michael Wonder on 14 Jan 2019
EMA approves Flutiform for children with asthma
14 January 2019 - The EMA has approved Flutiform pMDI for use in the treatment of children with asthma aged five years and over.
Flutiform pMDI is a combination of fluticasone propionate and formoterol in a single pMDI, otherwise known as a press-and-breathe aerosol inhaler.
Flutiform has been available in the UK for the treatment of asthma in adults and adolescents 12 or above since 2012, and has a tolerability profile supported by extensive clinical evidence and real-world use in these age groups, according to the firm.
